USPTO Finds SureGene Personalized Medicine Treatment Unpatentable Under Mayo

by Foley & Lardner LLP
Contact

In Ex Parte Timothy, the USPTO Patent Trial and Appeal Board (PTAB) affirmed the Examiner’s rejection of personalized medicine treatment claims. This decision highlights the PTAB’s willingness to invalidate claims that it finds similar to the claims at issue in Mayo. It also underscores the need for Congressional action to incentivize and protect investments in this important frontier of health care.

The Personalized Medicine Treatment Claims

The decision was rendered in U.S. patent application 13/269,365, assigned to SureGene LLC. According to the background section of the application, in the treatment of psychotic disorders, “there are individual differences in response to specific drugs based on differences in drug pharmacology and metabolism, combined with genetic differences between patients.” Also according to the application, “[t]here are currently no proven ways to identify which antipsychotic drug is optimal for a given patient. Thus, patients switch from one drug to another when response is not considered to be adequate or side effects are intolerable.” Indeed, “[o]n average, each patient may change medications three times for finding one that works.”

The application describes the invention as being “in part based on the finding that a genetic signature, which the inventors refer to as the Olanzapine Poor Response Predictor (OPRP), is a biomarker that can be used for selecting a more appropriate antipsychotic treatment plan for that particular subject. For example, the inventors have discovered that patients that are OPRP negative respond better than patients that are OPRP positive when treated with olanzapine, clozapine, or quetiapine.”

Claim 1 was identified as representative:

1. A method for treating a human subject having or suspected of having a psychotic disorder, comprising:
a) selecting a subject having or suspected of having a psychotic disorder and who has been determined to
have the OPRP genetic signature, wherein the OPRP genetic signature is defined as a genotype comprising a homozygous genotype for the T allele at rs11960832 and either a homozygous or heterozygous genotype for the T allele at rs7975477; and
b) treating the subject that was determined to have the OPRP signature with an antipsychotic treatment other than clozapine or quetiapine.

The PTAB Decision

The PTAB summarized the § 101 rejection on appeal:

The Examiner has rejected claims 1-10 as being directed to patent-ineligible subject matter. The Examiner finds that, under the standard set out in Mayo Collaborative Services v. Prometheus Labs., Inc., 566 U.S. 66 (2012), “the claims inform a relevant audience about certain laws of nature. The additional steps consist of well-understood, routine, conventional activity already engaged in by the scientific community. The additional steps, when viewed as a whole, add nothing significant beyond the sum of their parts taken separately.” (Final Action 5.)

The Examiner also had found:

  • the correlation between the OPRP genetic signature and response to clozapine or quetiapine treatment is a “law of nature” under Mayo
  • the “selecting” is not sufficient to transform the claim into eligible subject matter
  • the “treatment” step did not distinguish the claims from Mayo, because the claims at issue in that case also were directed to a method of treatment.

The PTAB agreed, and set forth the claims from Mayo in its decision:

  1. A method of optimizing therapeutic efficacy for treatment of an immune-mediated gastrointestinal disorder, comprising:
    (a) administering a drug providing 6–thioguanine to a subject having said immune-mediated gastrointestinal disorder; and
    (b) determining the level of 6–thioguanine in said subject having said immune-mediated gastrointestinal
    disorder,
    wherein levels of 6–thioguanine below or above certain thresholds indicate a need to increase or decrease, respectively, the amount of drug being administered.

The PTAB drew several analogies to the Mayo decision, including:

The Court [in Mayo] concluded that “[a]nyone who wants to make use of these laws must first administer a thiopurine drug and measure the resulting metabolite concentrations, and so the combination amounts to nothing significantly more than an instruction to doctors to apply the applicable laws when treating their patients.” …. Similarly here, anyone who wants to make use of the natural law–the relationship between the OPRP genetic signature and the lack of efficacy of clozapine or quetiapine –must first determine whether a given patient has the OPRP genetic signature before determining which antipsychotic medication to treat them with. Thus, claim 1 amounts to nothing significantly more than an instruction to doctors to apply the applicable law when treating their patients.

The PTAB rejected the argument that the claim should be eligible as a new use of a known drug, because “the treatment of schizophrenic patients with antipsychotic drugs other than clozapine or quetiapine does not represent a new use for the known antipsychotic drugs.” Thus, the PTAB did not give any weight to the patient selection steps when determining that the claim related to a known use of a known drug.

The PTAB also rejected the argument that the claim should be eligible by analogy to the USPTO’s amazonic acid example, asserting that “the cited exemplary claims address analysis of a different class of inventions that have been held to be patent-ineligible,” i.e., natural products that are analyzed under Myriad. The PTAB emphasized, as it has in other decisions, that it is not bound by the USPTO’s Subject Matter Eligibility Guidelines.

Inconsistency Won’t Incentivize Investment

Subject matter eligibility was a hot topic at the IPO Annual Meeting last week. Even though panelists didn’t agree on the best way to address the recent changes in this area of U.S. patent law, everyone agreed that predictability–the ability to know what is and what is not patentable–is essential to making sound business and investment decisions. In that context, it is striking that the PTAB relied on a 2012 Supreme Court decision (Mayo), even though SureGene had obtained several personalized medicine patents since that case was decided–including patents granted as recently as 2015.

The PTAB’s unwillingness to adhere to the USPTO’s Subject Matter Eligibility Guidelines also is disturbing, and makes the patent application process even more inconsistent and unpredictable. While the PTAB had grounds for distinguishing the “amazonic acid” claims, it did not address–or even expressly acknowledge–the diagnosing and treating claims of the “julitis” example, which are said to be eligible in an analysis that considers the contribution of the claimed “combination of steps,” gives weight to the fact that the combination “is not routine and conventional,” and finds “significantly more” in “ensur[ing] that patients who have julitis will be accurately diagnosed (due to the detection of JUL-1 in their plasma) and properly treated.” An Examiner following these Guidelines could grant claims that an Examiner not following the guidelines would not, and the PTAB might uphold the Examiner who did not follow the guidelines!

Also a hot topic at the IPO Annual Meeting was possible legislative changes to § 101. While not all stakeholders agreed that Congressional action is needed to address issues facing computer and business method patents, most agreed that diagnostic methods and personalized medicine should be brought back into the realm of eligible subject matter, such as by legislation that would at least abrogate Mayo, if not Myriad.

On this point, it is important to keep in mind that SureGene’s patent application at issue here was filed before the Supreme Court decision in Mayo. Thus, SureGene invested in this technology against a landscape where it would be patentable. How can we expect continued innovation in these fields without patent protection?

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Foley & Lardner LLP | Attorney Advertising

Written by:

Foley & Lardner LLP
Contact
more
less

Foley & Lardner LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.